1 / 21

Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in chondrosarcomas

12 th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006. Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in chondrosarcomas. Makoto Endo, 1 Tadaki Matsumura, 2 Umio Yamaguchi, 1 Fumihiko Nakatani, 1 Akira Kawai, 1 Hirokazu Chuman, 1

kerry
Download Presentation

Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in chondrosarcomas

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Cyclooxygenase-2 (COX-2) overexpressionis associated with a poor prognosis in chondrosarcomas Makoto Endo,1 Tadaki Matsumura,2 Umio Yamaguchi,1 Fumihiko Nakatani,1 Akira Kawai,1 Hirokazu Chuman,1 Yasuo Beppu,1 Tadashi Hasegawa2 1 Division of Orthopaedic Oncology, National Cancer Center Hospital, Tokyo, Japan 2 Department of Clinical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan

  2. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Background Chondrosarcoma The second most common malignant bone tumor A broad array of presentations The histologic grade is the standard for predicting the outcome

  3. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Grading ofchondrosarcomas The histologic grading system is separated intothree grades Based on 1. cellularity 2. nuclear atypia 3. pleomorphism Fletcher CDM, et al (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone, 2002.

  4. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Grade 1 In some borderline cases, exact histologic grading is difficult using only routine histopathologic examinations Grade 2 Grade 3

  5. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Cyclooxygenase-2 (COX-2) An isoform of COX A key enzyme that catalyzes the synthesis of prostaglandins (PGs) from arachidonic acid COX-2-derived PGsplay an important role in carcinogenesis 1. induceangiogenesis 2. inhibitapoptosisand immune surveillance 3. increase invasion and metastatic potential

  6. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Purpose To investigate the expression profile of COX-2 using immunohistochemical staining in formalin-fixed, paraffin-embedded chondrosarcoma specimens To confirm whether COX-2 expression is associated with prognosis

  7. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Materials & Methods 74 patients Sex: men, 37; women, 37 Age: 14 - 81 y/o (median, 50 y/o) Size: 2.7 - 32 cm (median, 8.0 cm)

  8. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Location: Axial skeleton, 47 (pelvis, 20; rib, 19; vertebra, 4; scapula, 3; skull base, 1) Long bones, 27 (femur, 10; humerus, 5; tibia, 5; fibula, 2; ulna, 1; others, 4)

  9. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Immunohistochemical analysis of COX-2 A monoclonal anti-COX-2 antibody (clone CX-294; 1:100; DakoCytomation) Definition of overexpression: More than 10% of the tumor cells stained

  10. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 • COX-2 staining in the chondrosarcomas was • consistently observed in atypical chondrocytes • with a strong and cytoplasmic pattern

  11. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 • ＜10% of cells stained • = Negative • ≧10% of cells stained • = Positive

  12. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Results (74 cases) Histologic grade Grade 1: 39 Grade 2: 32 Grade 3: 3 • COX-2 overexpression • Positive: 16 (22%) • Negative: 58 (78%)

  13. 12th CTOS Annual Meeting in Venice, Italy

  14. 12th CTOS Annual Meeting in Venice, Italy

  15. 12th CTOS Annual Meeting in Venice, Italy Cumulative Disease-specific Survival (%) 100 COX-2 overexpression (-) 90 80 70 60 50 COX-2 overexpression (+) 40 30 20 10 0 0 50 100 150 200 Months

  16. 12th CTOS Annual Meeting in Venice, Italy

  17. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Discussion The first immunohistochemical evidence that COX-2 overexpression is significantly associated with decreased survival

  18. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Discussion In the multivariate analysis, the only independent risk factor for a poor outcome was a high histologic grade. COX-2 overexpression was significantly associated with the histologic grade.

  19. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Discussion COX-2 overexpression can be definitively evaluated based on the proportion of stained tumor cells, enabling the subjectivity of interpretations to be minimized.

  20. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Conclusion COX-2 overexpression in chondro- sarcomas is a useful predictor of patient outcome that is strongly associated with histologic grade.

  21. 12th CTOS Annual Meeting in Venice, Italy 2-4, November, 2006 Acknowledgements • Pediatric oncology • Ako Hosono • Pathology • Kunihiko Seki • Secretarial assistance • Yuriko Kawaguchi Orthopaedic oncology Yuki Morimoto Yoshiyuki Suehara Eisuke Kobayashi Ken Takeda

More Related